Clinical trials: PET/CT Imaging
Cancer, Solid Tumor
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
The purpose of this Expanded Access Program (EAP) is to allow use of the investigational imaging agent, MNPR-101-DFO*-89Zr, with positron emission tomography/computed tomography (PET/CT) imaging, to non-invasively detect the…
- Conditions
- Cancer, Solid Tumor, Solid Tumor, Adult
- Trial name
- NCT06980506
- Testing
- MNPR-101-DFO*-89Zr
- Where
- United States
- Sponsor
- Monopar Therapeutics
NSCLC
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma
Retrospective study in patients with therapy-naive non small cell lung carcinoma correlating presurgical F18-FDG-PET/CT imaging texture analysis data with postsurgical molecular pathology data and clinical patient outcome.
- Trial name
- PANU (NCT04276025)
- Testing
- Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
- Volunteers
- 2,000 people
- Sponsor
- Klinikum Bayreuth GmbH
Prostate Cancer
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
- Trial name
- NCT06754085
- Testing
- Florastamin[18F] Injection
- Where
- China
- Volunteers
- 131 people
- Sponsor
- HTA Co., Ltd.
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON…
- Trial name
- NCT06750419
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 8 sites in China
- Volunteers
- 82 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer (Adenocarcinoma)
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time.
- Trial name
- NCT06655064
- Testing
- None- Observational
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer (Diagnosis)
Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
- Trial name
- NCT07615101
- Testing
- 68-Ga-NYM032
- Where
- 2 sites in China
- Volunteers
- 365 people
- Sponsor
- Norroy Bioscience Co., LTD
High Risk Prostate Carcinoma
[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
This is a multi-center, open-label, single arm Phase III clinical trial for the diagnostic efficacy assessment and safety evaluation by [18F]Florastamin PET/CT imaging examination to determine the presence of recurrent or…
- Trial name
- NCT05936658
- Testing
- [F-18]Florastamin
- Where
- 6 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- FutureChem
Positron-Emission Tomography, Metastatic Solid Tumors
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by immunohistochemical staining in patients with…
- Trial name
- iCorrelate (NCT03802123)
- Testing
- ⁸⁹Zr-Df-IAB22M2C
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- ImaginAb, Inc.
Diagnostic Imaging, Neoplasms
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY94-9392 in patients with cancer or inflammation.
- Trial name
- NCT01103310
- Testing
- BAY94-9392
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
The Main purpose of this project to study the uptake pattern of FLT-PET and it is value in assessing the malignant hematopoiesis in MPN within the pediatric age group, in terms of diagnosis, staging and monitoring response to…
- Conditions
- Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage, Primary Myelofibrosis, Prefibrotic Stage, Polycythemia Vera
- Trial name
- NCT03121599
- Testing
- Diagnostic (18F-FLT PET/CT)
- Where
- Qatar
- Volunteers
- 3 people
- Sponsor
- Hamad Medical Corporation
Metastatic Sarcoma, Esophageal Cancer
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to…
- Conditions
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- PHANTOM (NCT06298916)
- Testing
- 64Cu-LNTH-1363S
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Lantheus Medical Imaging
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Non Small Cell Lung Cancer
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
This is a multi-center Phase 1 b study designed to expand the patient safety using 99mTc-EC-DG with SPECT/CT imaging and to expand the patient radiation dosimetry and pharmacokinetic database using 99mTc-EC-DG in patients who…
- Trial name
- NCT00864110
- Testing
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), Technetium 99m ethylenedicysteine-deoxyglucose, 18 F fluorodeoxyglucose
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Cell>Point LLC
Diagnostic Imaging
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-4367 in patients with cancer
- Trial name
- NCT00975299
- Testing
- BAY86-4367
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 16 people
- Sponsor
- Bayer
Small Cell Lung Cancer and Breast Cancer
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
This study consists of two phases. The phase I study is designed to investigate the safety and tolerability of Satoreotide tetraxetan following fractionated i.v.
- Trial name
- SSTR2+ (NCT03773133)
- Testing
- Satoreotide tetraxetan, Satoreotide trizoxetan
- Where
- 8 sites in United States, Austria and 5 more
- Volunteers
- 9 people
- Sponsor
- Ipsen
Prostate Cancer
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
This is a single arm, open label study of up to 20 patients with prostate cancer scheduled for prostatectomy at the NIH Clinical Center.
- Trial name
- NCT01279785
- Testing
- 123I-MIP-1072
- Where
- United States
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Cancer Recurrent
A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
PYTHON is designed to establish the efficacy and safety of 18F-DCFPyL in comparison with that of 18F-fluorocholine, in patients with first biochemical recurrence (BCR) after initial definitive therapy (prostatectomy, external…
- Trial name
- Python (NCT04734184)
- Testing
- DCFPyL
- Where
- France
- Volunteers
- 217 people
- Sponsor
- Curium PET France
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
The purpose of this study was to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT).
- Trial name
- GuideView (NCT04838626)
- Testing
- [18F]CTT1057
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A.
- Trial name
- NCT02260817
- Testing
- 11C-choline Injection
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Global Isotopes, LLC d/b/a Zevacor Molecular
Focus of Study is Imaging Performance With the New Technology Compared With the Currently Available Technology.
Pilot Study Intended to Provide Input for Future Designs Using the PET Alpha Ring Detector
A standard PET/CT scanner is comprised of two different machines: An X-ray computed tomography scanner (CT), which gives information about your anatomy, and a Positron Emission Tomography scanner (PET) that provides information…
- Trial name
- NCT01731860
- Testing
- Additional PET Scan
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Philips Healthcare